AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03000465 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic colorectal surgery
Description: Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
Study NCT00471601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study NCT00471601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00471601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study NCT00471601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT03188640 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic gastric-bypass surgery
Description: Female participants with BMI >30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
Study NCT01785745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive therapeutic exercise
Description: Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
Study NCT01785745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapeutic exercise
Description: Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
Study NCT02063646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich extract
Description: Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
Study NCT02063646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
Study NCT04661124 — intervention group
Intervention type: DEVICE
Intervention: SPECTRALIS
Description: ophthalmic imaging device with head and chinrest
Study NCT04661124 — intervention group
Intervention type: DEVICE
Intervention: SPECTRALIS with Flex Module
Description: ophthalmic imaging device on mobile instrumentation stand
Study NCT02645266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
Study NCT04088786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
Study NCT00993720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
Study NCT00993720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
Study NCT04458428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS
Description: Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information.
Study NCT00993720 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: continuous insulin therapy
Description: after optimal treatment with insulin, patients continue on insulin for four weeks
Study NCT00772174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Metformin
Description: Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
Study NCT00772174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
Study NCT01150838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
Study NCT04116554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine.
Description: 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
Study NCT04116554 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 0.9%saline
Description: 20 ml of 0.9%saline will be injected on each side
Study NCT04886921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal muscle training
Description: Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
Study NCT02124291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Assisted Hatching
Description: The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
Study NCT00377676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloset
Description: Usual diabetes therapy plus Cycloset
Study NCT00377676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Diabetes Therapy plus placebo
Description: Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
Study NCT04378075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatiquinone
Description: Vatiquinone will be administered per the treatment arm description.
Study NCT04378075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vatiquinone-matching placebo will be administered per the treatment arm description
Study NCT04378075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vatiquinone-matching placebo will be administered per the treatment arm description
Study NCT01497379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical implantation of subretinal device
Description: surgical implantation of subretinal device
Study NCT01497379 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: surgical implantation of subretinal device
Description: intra-individual implant OFF
Study NCT01639898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Description: 2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
Study NCT04432129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBBIS II
Description: The IBBIS-II service consists of:~1. Mental health assessment.~2. Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~3. Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~4. Treatment consists of stepped care with structured treatment guidelines.~5. When the participant has obtained work the team continues to offer support.
Study NCT04432129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Service as Usual
Description: Service as usual consists of standard mental health care and vocational rehabilitation
Study NCT01639898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Description: 9 cycles of the Len-Dex combination
Study NCT03176394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLASTX Gel
Description: Foley Catheter lubricated with BLASTX Gel
Study NCT03176394 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: McKesson Jelly
Description: Foley Catheter lubricated with McKesson Jelly
Study NCT02299661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1093a
Description: DS-1093a, single oral doses up to 50 mg
Study NCT03927989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging plus nicotine replacement therapy
Description: Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
Study NCT03927989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care at Lung Cancer Screening
Description: Brief advice to quit smoking prior to lung cancer screening
Study NCT04383769 — intervention group
Intervention type: OTHER
Intervention: questionnaires survey
Description: data will be collected from the medical records already existed in the hospital and community-based organization (CBO) systems and entered into case report form (CRF). The expected number of participants is 5000. For each participant, the data will be collected prospectively for 24 months and retrospectively up to 5 years from the screening date. This study has no intervention and will not alter ART services whether be standard or DSD-ART at hospitals.
Study NCT04456764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SaFTiE
Description: A multi-modal fatigue risk management program.
Study NCT04456764 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo Control
Description: A multi-modal teamwork assessment program.
Study NCT00922610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
Study NCT01831687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day
Study NCT01831687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets USP 600mg
Description: Etodolac Extended Release Tablets USP 600mg once a day
Study NCT01831687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day
Study NCT01831687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Extended Release Tablets 600mg
Description: Etodolac Extended Release Tablets 600mg once a day
Study NCT02664038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Training
Description: Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
Study NCT02664038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Training
Description: Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
Study NCT03609177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Communication Skills Training
Description: Communication skills training
Study NCT03609177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinician Communication Skills Training
Description: Communication skills training
Study NCT03609177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) Decisions Videos Decisions Aids
Description: ACP Decisions video decision aids
Study NCT03609177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advance Care Planning (ACP) Decisions Videos Decisions Aids
Description: ACP Decisions video decision aids
Study NCT03609177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Declarations (ViDec)
Description: Recording of patient advance care planning videos
Study NCT03609177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video Declarations (ViDec)
Description: Recording of patient advance care planning videos
Study NCT03903107 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional fluoroscopy guided Conduction System Pacing(CSP)
Description: conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
Study NCT03903107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)
Description: Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
Study NCT01073488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization, HBLSS and facility improvement
Description: Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
Study NCT02504866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Description: Exercise training of vigorous intensity
Study NCT02504866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light to moderate exercise
Description: Exercise training of light to moderate intensity
Study NCT04368923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Patients receive oxygen therapy
Study NCT04368923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients receive physical therapy
Study NCT02928341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved water supply
Study NCT00024518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30,000 units hrINF-alpha
Study NCT00024518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5,000 hrINF-alpha
Study NCT00024518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo was prepared as saline alone with 6mg human serum albumin (HSA).
Study NCT04408443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938 + Vitamine D3
Description: Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
Study NCT04408443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sunflower oil, medium chain triglycerides, silicon dioxide
Study NCT01125423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
Study NCT01125423 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
Study NCT00870714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
Study NCT01125423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
Study NCT01125423 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin Biopsy
Description: Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
Study NCT01125423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin Biopsy
Description: Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
Study NCT00698958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
Description: Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
Study NCT00698958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hospital based adaptation to non- invasive mechanical ventilation for 7 days
Description: Hospital based adaptation to non- invasive mechanical ventilation for 7 days
Study NCT01599650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT01599650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: laser photocoagulation
Study NCT01599650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: laser photocoagulation
Study NCT01243944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib tablets
Description: Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
Study NCT01243944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Available Therapy (BAT)
Description: Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Study NCT04526171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaparshun
Description: Participants in the intervention clusters were encouraged to improve their existing toilets.
Study NCT01094600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic Human Secretin
Description: Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
Study NCT04107844 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Novel facilitating agility dual-task test combined with already known tests
Description: We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
Study NCT03652324 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: method
Description: to compare the use of general anesthesia and deep sedation
Study NCT02305303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diary
Description: A diary written prospectively during the ICU stay by the staff and relatives
Study NCT01581476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: 10mg daily for a minimum period of 2 years
Study NCT01581476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
Study NCT01581476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive statin placebo and ACEI placebo